Literature DB >> 34926224

Postoperative analgesic effect of parecoxib sodium local anesthesia in patients with breast cancer through systematic review and meta-analysis.

Fangfang Chen1, Yangfan Fan1, Saisa Zhu1.   

Abstract

BACKGROUND: Postoperative pain can seriously affect a patient's recovery, and parecoxib sodium has a good analgesic effect. However, there is a lack of clinically systematic analyses of the effects of parecoxib sodium on postoperative pain in breast cancer patients. The aim of the present study was to systematically evaluate the efficacy and safety of parecoxib sodium local anesthesia in the treatment of postoperative pain in breast cancer patients.
METHODS: Literature published from January 2010 to December 2020 was searched in the China National Knowledge Infrastructure database, Wanfang database, PubMed, and Cochrane Library. Literature on randomized controlled trials of parecoxib sodium local anesthesia in patients with breast cancer was collected. Method of treatment was extracted and literature quality was assessed. Meta-analyses of included literature were performed using RevMan 5.3.
RESULTS: A total of 17 randomized controlled trials were included, with a total of 1,032 breast cancer surgery patients. The experimental group was treated with parecoxib sodium anesthesia, and the control group was treated with other anesthesia methods. The meta-analysis results showed that there were obvious differences among visual analogue scale (VAS) score of the experimental group and control group 2 h after surgery [mean difference (MD): -0.79; 95% confidence interval (CI): -1.29 to -0.29; P=0.002], 4 h (MD =-0.77; 95% CI: =-1.51 to -0.03; P=0.04), 6 h (MD: -1.10; 95% CI: -1.41 to -0.80; P<0.00001), 8 h (MD: -0.66; 95% CI: -1.00 to -0.33; P=0.0001), 12 h (MD: -0.92; 95% CI: -1.24 to -0.60; P<0.00001), 24 h (MD: -0.86; 95% CI: -1.15 to -0.58; P<0.00001), and 48 h (MD: -0.90; 95% CI: -1.47 to -0.33; P=0.002). Moreover, visual analog scale score and the postoperative controlled analgesia frequency of patients in the experimental group (MD: -2.08; 95% CI: -2.88 to -1.27; P<0.00001) and the incidence of adverse reactions (odds ratio: 0.52; 95% CI: 0.34-0.80; P=0.002) were significantly reduced. DISCUSSION: Parecoxib sodium local anesthesia for breast cancer patients has good postoperative analgesia and treatment safety. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Parecoxib sodium; breast cancer; meta-analysis; postoperative analgesia; surgery

Year:  2021        PMID: 34926224      PMCID: PMC8637069          DOI: 10.21037/gs-21-632

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  19 in total

1.  Postoperative Pain after Endodontic Retreatment Using Rotary or Reciprocating Instruments: A Randomized Clinical Trial.

Authors:  Daniel Comparin; Edson Jorge Lima Moreira; Erick M Souza; Gustavo De-Deus; Ana Arias; Emmanuel João Nogueira Leal Silva
Journal:  J Endod       Date:  2017-05-03       Impact factor: 4.171

2.  Optimal postoperative pain management: redefining the role for opioids.

Authors:  Markus W Hollmann; James P Rathmell; Philipp Lirk
Journal:  Lancet       Date:  2019-04-13       Impact factor: 79.321

3.  Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial.

Authors:  James S Khan; Nicole Hodgson; Stephen Choi; Susan Reid; James E Paul; Nicole J Look Hong; Claire Holloway; Jason W Busse; Ian Gilron; D Norman Buckley; Michael McGillion; Hance Clarke; Joel Katz; Sean Mackey; Ronen Avram; Kayla Pohl; Purnima Rao-Melacini; P J Devereaux
Journal:  J Pain       Date:  2019-03-05       Impact factor: 5.820

4.  Tramadol use is associated with enhanced postoperative outcomes in breast cancer patients: a retrospective clinical study with in vitro confirmation.

Authors:  Myoung H Kim; Ju E Oh; Seho Park; Joo H Kim; Ki Y Lee; Sun J Bai; Hyunjik Song; Hye J Hwang; Dong W Kim; Young C Yoo
Journal:  Br J Anaesth       Date:  2019-10-05       Impact factor: 9.166

5.  Role of Parecoxib Sodium in the Multimodal Analgesia after Total Knee Arthroplasty: A Randomized Double-blinded Controlled Trial.

Authors:  Yan-Yan Bian; Long-Chao Wang; Wen-Wei Qian; Jin Lin; Jin Jin; Hui-Ming Peng; Xi-Sheng Weng
Journal:  Orthop Surg       Date:  2018-11       Impact factor: 2.071

6.  Transcutaneous electrical nerve stimulation (TENS) reduces pain and postpones the need for pharmacological analgesia during labour: a randomised trial.

Authors:  Licia Santos Santana; Rubneide Barreto Silva Gallo; Cristine Homsi Jorge Ferreira; Geraldo Duarte; Silvana Maria Quintana; Alessandra Cristina Marcolin
Journal:  J Physiother       Date:  2015-12-11       Impact factor: 7.000

7.  Perioperative analgesia with parecoxib sodium improves postoperative pain and immune function in patients undergoing hepatectomy for hepatocellular carcinoma.

Authors:  Run-Dong Wang; Jian-Yu Zhu; Yu Zhu; Yong-Sheng Ge; Ge-Liang Xu; Wei-Dong Jia
Journal:  J Eval Clin Pract       Date:  2019-08-12       Impact factor: 2.431

Review 8.  Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Ajit S Rai; James S Khan; Jasneet Dhaliwal; Jason W Busse; Stephen Choi; P J Devereaux; Hance Clarke
Journal:  J Plast Reconstr Aesthet Surg       Date:  2017-06-09       Impact factor: 2.740

9.  The safety profile of parecoxib for the treatment of postoperative pain: a pooled analysis of 28 randomized, double-blind, placebo-controlled clinical trials and a review of over 10 years of postauthorization data.

Authors:  Stephan A Schug; Bruce Parsons; Chunming Li; Feng Xia
Journal:  J Pain Res       Date:  2017-10-10       Impact factor: 3.133

10.  Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS.

Authors:  Jie Hu; Bing-Feng Lv; Wen-Jing Guo; Bo-Wen Wang; Di Miao; Xiang-Jun Qiu; Xing-Peng Chen
Journal:  Biomed Res Int       Date:  2020-08-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.